

Press Release 26 March 2015

Infant Bacterial Therapeutics receives additional funding from mother company BioGaia

Infant Bacterial Therapeutics (IBT) continues its efforts to develop a drug to prevent necrotizing enterocolitis (NEC) which is a rare and fatal disease that affects premature infants. IBT plans to start a study on the safety and tolerability of the product in 2015. To allow for the study start, BioGaia will support IBT with an additional investment of 520 000 US dollars.

In November 2013, the Board of BioGaia invested 42 million SEK in IBT to conduct the early stages of the pharmaceutical development of a preventive therapy for NEC following pharmaceutical regulations.

During 16 months of activity, IBT has achieved meaningful milestones including, receipt of Orphan Drug Designation for the prevention of NEC in both US and Europe and has consulted both FDA and EMA on a harmonized drug development program including clinical trial designs and manufacturing process.

To conduct the upcoming clinical trials, IBT is currently seeking external financing and investigating partnership opportunities.

“At IBT we will pursue our efforts towards providing a therapeutic solution to prevent such a devastating disease as NEC. We are pleased to see that BioGaia is providing this additional funding to IBT,” says Staffan Strömberg, CEO, Infant Bacterial Therapeutics.

For additional information please contact

Staffan Strömberg, CEO, telephone: +46 8 410 145 55

Infant Bacterial Therapeutics AB

Gamla Brogatan 11, 111 20 Stockholm, Sweden

Phone: +46 (0) 84 101 4555

E-mail: info@ibtherapeutics.com

www.ibtherapeutics.com